Business Context and Reporting Period
This Form 8-K reports on the results of the 2025 Annual Meeting of Stockholders held by Marker Therapeutics, Inc. on June 6, 2025. The company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC under the symbol MRKR.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
Of the 11,314,835 shares outstanding as of the record date, 7,629,048 shares (67.43%) were present or represented by proxy. The stockholders voted on three proposals:
- Proposal 1 (Election of Directors): All four nominees (David Eansor, Steven Elms, Katharine Knobil, and Juan Vera) were elected. Broker non-votes totaled 2,821,927.
- Proposal 2 (Executive Compensation): The advisory approval of named executive officer compensation was approved with 4,449,829 votes for, 343,434 against, and 13,857 abstentions. Broker non-votes totaled 2,821,927.
- Proposal 3 (Auditor Ratification): The selection of Marcum LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with 7,494,386 votes for, 80,755 against, and 53,907 abstentions. There were no broker non-votes.
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, or specific risk factors. It references a definitive proxy statement filed on April 24, 2025, for further details on the proposals.
Investor Verification Checklist
- Verify the definitive proxy statement filed on April 24, 2025, for detailed background on the director nominees and executive compensation.
- Confirm the appointment of Marcum LLP as the auditor for the fiscal year ending December 31, 2025.
- Review the company's most recent 10-K or 10-Q filings for financial performance data, as this 8-K contains no financial metrics.